Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

A Phase I/II Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of Glofitamab As Monotherapy and in Combination with R-ICE Chemoimmunotherapy in Children and Young Adults with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (iMATRIX-GLO)

Birgit Burkhardt, Gianluca Rossato, Mark Dixon, David John Carlile, Steven Dmytrasz, Jade Wulff, Raluca Negricea, Beate Wulff

Blood (2023) 142 (Supplement 1): 3096.

https://doi.org/10.1182/blood-2023-174929

Published: 2023

Journal Articles

New Tocilizumab (TCZ) Dosing Guidance for T-Cell Engaging Bispecific Antibody-Related Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL): Insights from Pooled Clinical Trial Safety Experience and Quantitative Clinical Pharmacology (qCP) Analyses

Candice Jamois, David C. Turner, Leonid Gibiansky, Feifei Li, Nicolas Frey, Jean-Francois Menuet, Leonardo Roque Pereira, Linda Lundberg, Elena Guerini, David John Carlile, James Relf, Michael C. Wei, Antonia Kwan, Susan Grange

Blood (2023) 142 (Supplement 1): 1742.

https://doi.org/10.1182/blood-2023-177679

Published: 2023

Journal Articles

Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Blood (2022) 140 (Supplement 1): 9443–9445.

https://doi.org/10.1182/blood-2022-158245

Published: 2022

Journal Articles

Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study

Blood (2022) 140 (Supplement 1): 846–849.

https://doi.org/10.1182/blood-2022-157058

Published: 2022

Journal Articles

Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Andrew J Davies, Josh Caddy, Katy McLaughlin, Christopher Wignall, Robert Waugh, Graham P. Collins, Louise Stanton, Geoff N Saunders, Thomas Cummin, Anna Schuh, Kirit M. Ardeshna, Andrew K. McMillan, John Radford, David John Lewis, Adam R Coleman, Gareth Griffiths, Cathy Burton, Sharon Barrans, Peter Johnson

Blood (2022) 140 (Supplement 1): 9478–9479.

https://doi.org/10.1182/blood-2022-163499

Published: 2022

Journal Articles

Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study

Blood (2022) 140 (Supplement 1): 557–560.

https://doi.org/10.1182/blood-2022-159123

Published: 2022

Journal Articles

Pembrowm: Results of a Multi-Centre Phase II Trial Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia

Jaimal Kothari, Toby A. Eyre, Ali Rismani, Helen McCarthy, Angela Collins, David John Lewis, Suzanne O Arulogun, William Wilson, Laura Clifton-Hadley, Darren Edwards, Kushani Ediriwickrema, Rebecca Auer, Guy Pratt, Ruth M. de Tute, Roger G Owen, Shirley D'Sa

Blood (2022) 140 (Supplement 1): 3624–3626.

https://doi.org/10.1182/blood-2022-167158

Published: 2022

Journal Articles

Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study

Blood (2021) 138 (Supplement 1): 391.

https://doi.org/10.1182/blood-2021-147599

Published: 2021

Journal Articles

Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study

Blood (2021) 138 (Supplement 1): 381.

https://doi.org/10.1182/blood-2021-149138

Published: 2021

Journal Articles

LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenström's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study

Blood (2020) 136 (Supplement 1): 8–10.

https://doi.org/10.1182/blood-2020-134314

Published: 2020

Journal Articles

Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Andrew Davies, Josh Caddy, Katy Mercer, Geoff N Saunders, Louise Stanton, Graham P. Collins, MD DPhil, Thomas E C Cummin, MRCP MBBCh BSc, Anna Schuh, MD MRCP, PhD, Kirit M. Ardeshna, Andrew McMillan, John A. Radford, MD FMedSci, David John Lewis, MD, Adam Coleman, Gareth Griffiths, Cathy Burton, MBBChir, MA, MD FRCPath, Sharon Barrans, Peter Johnson, MD FRCP

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-134546

Published: 2020

Journal Articles

LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study

Blood (2020) 136 (Supplement 1): 35–37.

https://doi.org/10.1182/blood-2020-134970

Published: 2020

Journal Articles

IDH Mutations Are Associated with an Increased Risk of Coronary Artery Disease and Cardiotoxicity in Patients with Established AML

Badder Kattih, MD, Amir Shirvani, Piroska Klement, Abel Martin Garrido, Razif Gabdoulline, Alessandro Liebich, Maximilian Brandes, Anuhar Chaturvedi, PhD, Timon Seeger, Felicitas Thol, Gudrun Gohring, Prof., MD, Brigitte Schlegelberger, MD, Robert Geffers, PhD, David John, Udo Bavendiek, Johann Bauersachs, Arnold Ganser, Joerg Heineke, Michael Heuser

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-143026

Published: 2020

Journal Articles

Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data

Martin Hutchings, MD PhD, Rogier Mous, MD PhD, Michael Roost Clausen, MD PhD, Peter Johnson, MD FRCP, Kim M Linton, MBChB, PhD, Martine E.D. Chamuleau, MD PhD, David John Lewis, MD, Anna Sureda Balari, MD PhD, David Cunningham, MD FRCP, FMedSci, Roberto S Oliveri, MD PhD, Dena DeMarco, Brian Elliott, MD, Kuo-mei Chen, PhD, Pieternella J. Lugtenburg, MD PhD

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-133820

Published: 2020

Journal Articles

AVAIL-T: A Phase 2a Trial of Avelumab, and Anti-PD-L1 Antibody, in Relapsed and Refractory Peripheral T-Cell Lymphoma (PTCL)

Matthew J Ahearne, Charlotte Gaskell, BSc, MSc, Aimee E Jackson, BSc, MSc, Clare Morland, PhD, Louise Hopkins, Nadia Nawaz, Matthew A Timmins, Christopher P Fox, MD PhD, Graham P. Collins, MD DPhil, Andrew Davies, David John Lewis, MD, Kate Cwynarski, Kim Linton, MBChB, MRCP, PhD, Pam McKay, MD, Rod Johnson, Simon D. Wagner

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-136061

Published: 2020

Journal Articles

The Burden of Clinically Significant Bleeding, Thrombocytopenia and Platelet Transfusions in Myelodysplastic Syndromes

Kathleen Pao Lynn Cheok, MBBS, Rakchha Chhetri, MBBS, Li Yan A Wee, BSc (Hons), Arabelle Salvi, Bachelor of Pharmacy, Simon McRae, MD MBBS, MSc, David John Roxby, B App Sc, M App Sc, ARCPA, Deepak Singhal, MBBS, MD FRACP, FRCPA, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD

Blood (2019) 134 (Supplement_1): 719.

https://doi.org/10.1182/blood-2019-125273

Published: 2019

Journal Articles

Red Cell Alloimmunisation Is Associated with Increased Red Cell Transfusion Requirements in Myelodysplastic Syndrome

Rakchha Chhetri, MBBS, Amilia Wee, BSc (Hons), Romi Sinha, MBBS, Monika M Kutyna, MSc, Soumya Gupta, Lakshmi Nath, MDDM,FRCPA, Shriram V. Nath, MDDM, FRCPA, FRACP, Nicholas Wickham, FRCPA, FRACP, FRCPath, Ian D Lewis, MBBS,PhD, David M Ross, Luen Bik To, MBBS, FRACP, FRCPA, PhD, Deepak Singhal, MBBS, MDFRACP, FRCPA, David John Roxby, B App Sc, M App Sc, ARCPA, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD

Blood (2018) 132 (Supplement 1): 1826.

https://doi.org/10.1182/blood-2018-99-115848

Published: 2018

Journal Articles

Red Cell Alloimmunisation Is Associated with Development of Autoantibodies and Increased Red Cell Transfusion Requirements in Myelodysplastic Syndromes (MDS)

Deepak Singhal, MBBS, MD FRCPA, FRACP, Monika M Kutyna, MSc, Rakchha Chhetri, MBBS, Amilia Wee, BSc (Hons), Sophia Hague, Lakshmi Nath, MDDM,FRCPA, Shriram V Nath, MBBS, DM, FRCPA, Romi Sinha, MBBS, Nicholas Wickham, FRCPA,FRACP,FRCPath, Ian D Lewis, MBBS, PhD FRACP, FRCPA, David M Ross, MBBS, PhD FRACP, FRCPA, Peter G Bardy, MBBS, FRACP, FRCPA, FRCPath, Luen Bik To, MBBS, FRACP, FRCPA, PhD, John Reynolds, PhD, Erica Wood, David John Roxby, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD

Blood (2017) 130 (Supplement 1): 2411.

https://doi.org/10.1182/blood.V130.Suppl_1.2411.2411

Published: 2017

Journal Articles

Prognostic Factors and the Impact of Frontline Therapy in Peripheral T-Cell Lymphoma: A Multicenter Australian Study

James Anton Kuzich, MBBS, Andrew Peter Hutchison, MBBS, Kenneth Lim, MBBS, Matthew P.F. Wright, MBBS, FRCPA, FRACP, Gavin Cull, MB, BS, FRACP, FRCPA, Michael F. Leahy, FRACP,FRCPath,FRCP, David John Longstaff Joske, Dejan Radeski, MBBS, FRACP, FRCPA, Duncan Purtill, MBBS,FRCPA,FRACP

Blood (2017) 130 (Supplement 1): 1524.

https://doi.org/10.1182/blood.V130.Suppl_1.1524.1524

Published: 2017

Journal Articles

Efficacy and Safety of Melphalan 140mg/m 2 Conditioned Autologous Stem Cell Transplantation in Elderly Pre-Dialysis and Dialysis Patients with Multiple Myeloma

Hatem Ali, MBBS, Baharani Jyoti, MBBS, FRCP, Shankaranarayana Paneesha, MD, Richard Lovell, Alex George Kanellopoulos, MD, Evgenia Xenou, MD, Iman Qureshi, MBBS, MRCP, Lorna Cain, Maria Kaparou, David John Sutton, MBBChir, MRCP, BSc, Rebecca Pryor, MB, MRCP, Emmanouil Nikolousis, PhDMBBS,FRCPath,MBA, Bhuvan Kishore, MBBS, MRCP, FRCPath

Blood (2016) 128 (22): 5822.

https://doi.org/10.1182/blood.V128.22.5822.5822

Published: 2016

NARROW

A Phase I/II Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of Glofitamab As Monotherapy and in Combination with R-ICE Chemoimmunotherapy in Children and Young Adults with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (iMATRIX-GLO)

Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study

Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study

Pembrowm: Results of a Multi-Centre Phase II Trial Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia

Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study

Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study

LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenström's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study

Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study

IDH Mutations Are Associated with an Increased Risk of Coronary Artery Disease and Cardiotoxicity in Patients with Established AML

Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data

AVAIL-T: A Phase 2a Trial of Avelumab, and Anti-PD-L1 Antibody, in Relapsed and Refractory Peripheral T-Cell Lymphoma (PTCL)

The Burden of Clinically Significant Bleeding, Thrombocytopenia and Platelet Transfusions in Myelodysplastic Syndromes

Red Cell Alloimmunisation Is Associated with Increased Red Cell Transfusion Requirements in Myelodysplastic Syndrome

Red Cell Alloimmunisation Is Associated with Development of Autoantibodies and Increased Red Cell Transfusion Requirements in Myelodysplastic Syndromes (MDS)

Prognostic Factors and the Impact of Frontline Therapy in Peripheral T-Cell Lymphoma: A Multicenter Australian Study

Efficacy and Safety of Melphalan 140mg/m 2 Conditioned Autologous Stem Cell Transplantation in Elderly Pre-Dialysis and Dialysis Patients with Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only